两剂异源Ad26.ZEBOV与MVA-BN-Filo埃博拉疫苗方案在塞拉利昂儿童中的安全性和免疫原性:一项随机双盲对照试验
该随机双盲对照试验在塞拉利昂1-17岁健康儿童中评估两剂异源埃博拉疫苗方案(Ad26.ZEBOV首剂、MVA-BN-Filo次剂)的安全性及免疫原性。结果显示方案耐受良好,无疫苗相关严重不良事件,第二剂后21天各年龄组98%-99%儿童产生埃博拉病毒糖蛋白特异性结合抗体,提示该方案适用于儿童埃博拉病预防。
要点
- 两剂异源埃博拉疫苗方案在1-17岁儿童中耐受良好,未报告疫苗相关严重不良事件。
- 第二剂后21天,98%-99%儿童产生埃博拉病毒糖蛋白特异性结合抗体。
- 各年龄组常见 solicited 局部不良事件为注射部位疼痛,全身事件为头痛或发热。
核心结论
- Ad26.ZEBOV与MVA-BN-Filo埃博拉疫苗方案在1-17岁儿童中耐受良好且无安全性担忧。
- 该方案诱导了稳健的体液免疫应答,提示适合用于儿童埃博拉病毒病预防。
研究设计与样本
- 在塞拉利昂Kambia区三个诊所开展的随机、双盲、对照试验,纳入1-17岁健康儿童和青少年576名,按3:1随机分配。
- 受试者分三个年龄队列(12-17岁、4-11岁、1-3岁),各192名。
- 埃博拉疫苗组首剂肌注Ad26.ZEBOV(5×10^10病毒颗粒),第57天肌注MVA-BN-Filo(1×10^8感染单位);对照组首剂肌注MenACWY,第57天注射安慰剂。
主要发现
- 首次和第二次接种后7天内,各年龄组最常见的 solicited 局部不良事件为注射部位疼痛,频率从1-3岁安慰剂组的0%(0/48)到4-11岁Ad26.ZEBOV组的21%(30/144)。
- 12-17岁和4-11岁队列首次和第二次接种后7天内最常见的 solicited 全身不良事件为头痛,1-3岁队列为发热。
- 首次和第二次接种后最常见的非 solicited 不良事件为疟疾,所有年龄队列均如此,与疫苗类型无关。
- MenACWY接种后,一名3岁受试者出现严重血小板减少症;未观察到其他临床显著实验室异常,未报告埃博拉疫苗方案相关严重不良事件,无治疗相关死亡。
临床怎么用
- 该两剂异源埃博拉疫苗方案在1-17岁儿童中安全性良好且免疫原性高,可考虑用于儿童埃博拉病毒病预防。
- 临床接种时需关注注射部位疼痛、头痛或发热等常见不良事件,并监测罕见严重不良事件。
局限性
- 原文未明确报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Children account for a substantial proportion of cases and deaths from Ebola virus disease. We aimed to assess the safety and immunogenicity of a two-dose heterologous vaccine regimen, comprising the adenovirus type 26 vector-based vaccine encoding the Ebola virus glycoprotein (Ad26.ZEBOV) and the modified vaccinia Ankara vector-based vaccine, encoding glycoproteins from the Ebola virus, Sudan virus, and Marburg virus, and the nucleoprotein from the Tai Forest virus (MVA-BN-Filo), in a paediatric population in Sierra Leone. METHODS: This randomised, double-blind, controlled trial was done at three clinics in Kambia district, Sierra Leone. Healthy children and adolescents aged 1-17 years were enrolled in three age cohorts (12-17 years, 4-11 years, and 1-3 years) and randomly assigned (3:1), via computer-generated block randomisation (block size of eight), to receive an intramuscular injection of either Ad26.ZEBOV (5 × 1010 viral particles; first dose) followed by MVA-BN-Filo (1 × 108 infectious units; second dose) on day 57 (Ebola vaccine group), or a single dose of meningococcal quadrivalent (serogroups A, C, W135, and Y) conjugate vaccine (MenACWY; first dose) followed by placebo (second dose) on day 57 (control group). Study team personnel (except for those with primary responsibility for study vaccine preparation), participants, and their parents or guardians were masked to study vaccine allocation. The primary outcome was safety, measured as the occurrence of solicited local and systemic adverse symptoms during 7 days after each vaccination, unsolicited systemic adverse events during 28 days after each vaccination, abnormal laboratory results during the study period, and serious adverse events or immediate reportable events throughout the study period. The secondary outcome was immunogenicity (humoral immune response), measured as the concentration of Ebola virus glycoprotein-specific binding antibodies at 21 days after the second dose. The primary outcome was assessed in all participants who had received at least one dose of study vaccine and had available reactogenicity data, and immunogenicity was assessed in all participants who had received both vaccinations within the protocol-defined time window, had at least one evaluable post-vaccination sample, and had no major protocol deviations that could have influenced the immune response. This study is registered at ClinicalTrials.gov, NCT02509494. FINDINGS: From April 4, 2017, to July 5, 2018, 576 eligible children or adolescents (192 in each of the three age cohorts) were enrolled and randomly assigned. The most common solicited local adverse event during the 7 days after the first and second dose was injection-site pain in all age groups, with frequencies ranging from 0% (none of 48) of children aged 1-3 years after placebo injection to 21% (30 of 144) of children aged 4-11 years after Ad26.ZEBOV vaccination. The most frequently observed solicited systemic adverse event during the 7 days was headache in the 12-17 years and 4-11 years age cohorts after the first and second dose, and pyrexia in the 1-3 years age cohort after the first and second dose. The most frequent unsolicited adverse event after the first and second dose vaccinations was malaria in all age cohorts, irrespective of the vaccine types. Following vaccination with MenACWY, severe thrombocytopaenia was observed in one participant aged 3 years. No other clinically significant laboratory abnormalities were observed in other study participants, and no serious adverse events related to the Ebola vaccine regimen were reported. There were no treatment-related deaths. Ebola virus glycoprotein-specific binding antibody responses at 21 days after the second dose of the Ebola virus vaccine regimen were observed in 131 (98%) of 134 children aged 12-17 years (9929 ELISA units [EU]/mL [95% CI 8172-12 064]), in 119 (99%) of 120 aged 4-11 years (10 212 EU/mL [8419-12 388]), and in 118 (98%) of 121 aged 1-3 years (22 568 EU/mL [18 426-27 642]). INTERPRETATION: The Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen was well tolerated with no safety concerns in children aged 1-17 years, and induced robust humoral immune responses, suggesting suitability of this regimen for Ebola virus disease prophylaxis in children. FUNDING: Innovative Medicines Initiative 2 Joint Undertaking and Janssen Vaccines & Prevention BV.
引用
- Afolabi MO, Ishola D, Manno D, et al. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. Lancet Infect Dis. 2021. PMID: 34529962. doi:10.1016/S1473-3099(21)00128-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。